Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity

癌症和自身免疫中 COVID-19 感染的免疫调节

基本信息

批准号：
10680631
负责人：
Ignacio E. Sanz
金额：
$ 35.92万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-30 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10680631
关键词：
2019-nCoV ATAC-seq Accounting Acute Age Antibodies Antibody Repertoire Antiviral Response Autoimmune Autoimmune Diseases Autoimmunity B cell therapy B-Lymphocytes Biological Assay COVID-19 COVID-19 vaccination COVID-19 vaccine Cancer Patient Cell Compartmentation Cell physiology Cells Cellular Indexing of Transcriptomes and Epitopes by Sequencing Cessation of life Clinical Collaborations Development Disease Equilibrium Event Fatal Outcome Flow Cytometry Generations Heterogeneity Human Immune Immune Tolerance Immune response Immunoglobulin-Secreting Cells Immunologic Memory Immunologics Incidence Individual Infection Interferons Knowledge Life Longevity Malignant Neoplasms Measures Mediating Memory Memory B-Lymphocyte Molecular Monoclonal Antibodies Mus Outcome Pathogenesis Pathogenicity Pathologic Pathology Pathway interactions Patients Phase Phenotype Plasma Cells Population Regulation Respiratory Failure SARS-CoV-2 infection Severities Severity of illness Systemic Lupus Erythematosus TLR7 gene Vaccination Viral Work autoreactivity clinical heterogeneity immune checkpoint blockade immune-related adverse events immunoregulation neutralizing antibody novel programs response severe COVID-19 standard of care transcriptome sequencing

项目摘要

Abstract COVID-19 infection is greatly heterogenous. Individuals with underlying immune dysregulation, will have abnormal responses to COVID-19, thereby accounting for different short-term outcomes and memory formation. Specifically, emerging evidence indicates poor outcomes in autoimmune and cancer patients. We propose that autoimmune patients and severe COVID-19 infection will share an exacerbated pathological response while cancer patients with disease-associated or treatment-induced immune deficiency, will fail to mount a protective anti-viral response. Here, we shall interrogate the effector B cell response to SARS-CoV-2 to identify determinants of protective and pathogenic responses in HC and autoimmune subjects.

抽象的 COVID-19 感染具有很大的异质性。患有潜在免疫失调的个体，对 COVID-19 会有异常反应，从而导致不同的短期结果和记忆的形成。具体来说，新出现的证据表明自身免疫性疾病的结果不佳和癌症患者。我们建议自身免疫患者和严重的 COVID-19 感染者当癌症患者患有与疾病相关或治疗引起的免疫缺陷，将无法产生保护性抗病毒反应。在这里，我们应询问效应 B 细胞对 SARS-CoV-2 的反应，以确定保护性的决定因素 HC 和自身免疫受试者的致病反应。